Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline NEWS PROVIDED BY Alphyn Biologics Dec 12, 2025, 07:30 ET Financing funds the global Phase 2b clinical trial in atopic dermatitis and Phase 2 clinical program in molluscum contagiosum ANNAPOLIS, Md., Dec. 12, 2025 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing…
Alphyn Expands Patent Estate with New U.S. Patent for Atopic Dermatitis Therapeutic NEWS PROVIDED BY Alphyn Biologics Oct 27, 2025, 07:30 ET Patent covers active pharmaceutical ingredient with protection until 2041 ANNAPOLIS, Md., Oct. 27, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and Trademark Office…
15th Georg RAJKA International Symposium on Atopic Dermatitis Presentation: Zabalafin Hydrogel – A Novel Topical Botanical Drug That Addresses the Four Demons of Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics October 27, 2025, 07:30 ET 1168_Neal-KOLLER_phase-2b-trial-of-zabalafin-hydrogel-a-novel-topical-botanical-drug-that-addresses-the-four-demons-of-atopic-dermatitis CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
EADV Congress 2025 Poster Presentation: Zabalafin Hydrogel – A Novel, Safe, and Effective Topical Botanical Drug That Comprehensively Addresses the Four Demons of Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics September 23, 2025, 07:30 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195
2025 Integrative Dermatology Summit Poster Presentation: Zabalafin Hydrogel, A Novel Topical Botanical Drug That Addresses The Four Demons of Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics August 12, 2025, 07:30 ET CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195